Cysteamine is a medication being studied as an additional treatment alongside standard tuberculosis therapy. It works differently from traditional TB medications by targeting the patient’s immune system (the host) rather than directly attacking the bacteria. This approach could potentially improve the effectiveness of standard tuberculosis treatment. Cysteamine is already known and used for other medical conditions, but in this trial, it’s being studied for a new use (off-label) in treating tuberculosis.

Standard Tuberculosis (TB) therapy is the established combination of antibiotics used to treat TB infections. This therapy typically includes several medications that work together to kill the tuberculosis bacteria. The standard treatment helps eliminate the infection and prevent the bacteria from becoming resistant to the medications.

Pulmonary Tuberculosis – A bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs. The disease typically develops gradually, with bacteria slowly multiplying in the lungs and creating small patches of infection. As the infection progresses, it can create small holes in the lung tissue and cause inflammation. Common manifestations include persistent cough, chest pain, and the production of mucus. The infection can spread within the lungs, causing areas of damaged tissue and inflammation to grow larger over time. The condition can be passed from person to person through air droplets when someone with active tuberculosis coughs or sneezes.